{"gene":"IL1A","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1988,"finding":"The IL-1 receptor was cloned by direct expression strategy from mouse T cells; the receptor binds both IL-1α and IL-1β, has an extracellular domain of 319 amino acids composed of three immunoglobulin-like domains, and a cytoplasmic domain of 217 amino acids. The cloned receptor product binds IL-1α and IL-1β indistinguishably from the native T cell IL-1R.","method":"cDNA expression cloning, receptor-binding assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct cDNA expression cloning with functional binding validation, foundational study","pmids":["2969618"],"is_preprint":false},{"year":1988,"finding":"Murine keratinocytes constitutively express IL-1α mRNA (but not IL-1β mRNA). LPS exposure increased IL-1α mRNA >10-fold with a sixfold increase in secreted IL-1 activity. UV irradiation modulated IL-1α expression in a dose-dependent manner. IL-1α expression decreased with terminal keratinocyte differentiation (high Ca²⁺) and increased with undifferentiated state (low Ca²⁺).","method":"Northern blotting, IL-1 bioassay, keratinocyte culture under defined Ca²⁺ conditions","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mRNA and bioactivity measurements, single lab, multiple conditions tested","pmids":["3258334"],"is_preprint":false},{"year":1989,"finding":"Chronic in vivo administration of IL-1α produced protein wasting with accelerated peripheral skeletal muscle protein loss while preserving liver protein content, a pattern distinct from simple caloric restriction. Decrease in skeletal muscle protein was accompanied by coordinate decreases in mRNAs for myosin heavy chain, myosin light chain, actin, and ribosomal RNA subunits.","method":"In vivo chronic cytokine administration in rats, protein fractionation, Northern blotting for muscle mRNAs","journal":"American Journal of Physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo functional experiment with molecular readouts, single lab","pmids":["2784290"],"is_preprint":false},{"year":1990,"finding":"Internalized IL-1α remains bound to its receptor intracellularly for at least 4 hours without degradation, and accumulates in purified nuclei as an IL-1–receptor complex. No IL-1 receptors were detected in untreated nuclei, suggesting IL-1-driven translocation of the cell surface IL-1R complex to the nucleus. This internalization correlated with IL-1 signal transduction events required for growth factor production.","method":"125I-IL-1α internalization, electron microscope autoradiography, nuclear fractionation, receptor-binding in isolated nuclei","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by EM autoradiography and fractionation with functional correlation, single lab","pmids":["2137488"],"is_preprint":false},{"year":1990,"finding":"IL-1β binds to human alpha-2-macroglobulin (H-α2M) forming a complex in a pH- and divalent cation-dependent (Zn²⁺, Cd²⁺, Cu²⁺, Ni²⁺) manner. H-α2M-bound IL-1β is partially biologically inactive; reduced thioredoxin releases bound IL-1β and restores IL-1-like bioactivity. Binding requires histidyl residues in H-α2M.","method":"125I-IL-1β binding assay, native PAGE, competition assay, thioredoxin release assay, two independent bioassays","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and release experiments with functional bioassay validation, single lab, multiple orthogonal methods","pmids":["1700994"],"is_preprint":false},{"year":1991,"finding":"The human IL-1R1 gene was mapped to chromosome 2q12, near the IL-1α and IL-1β loci at 2q13–2q21. The murine Il-1r1 gene was mapped to chromosome 1, showing synteny with human chromosome 2 but separated from the murine IL-1 genes on chromosome 2.","method":"Rodent-human hybrid cell segregation analysis, chromosomal in situ hybridization, restriction fragment length polymorphism analysis in interspecific backcrosses","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct chromosomal mapping by multiple methods, single study","pmids":["1672292"],"is_preprint":false},{"year":1995,"finding":"TNF-α and IL-1α, produced within the thymic microenvironment, are each necessary for early thymocyte maturation and CD4+CD8+ differentiation. Either cytokine induced CD25 expression on early immature thymocytes in a thymus reconstitution assay; absence of both (or either) blocked further T cell lineage commitment.","method":"Thymus reconstitution assay in irradiated mice, flow cytometry for CD25/CD4/CD8, genetic epistasis with cytokine neutralization","journal":"Science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo reconstitution assay with defined cellular phenotype, single lab","pmids":["7541554"],"is_preprint":false},{"year":1997,"finding":"NIK (NF-κB-inducing kinase) was identified as a MAP3K-related kinase that participates in NF-κB induction by IL-1. Expression of kinase-deficient NIK mutants blocked NF-κB induction by IL-1 (as well as by TNF and CD95 signaling), establishing NIK as part of a common NF-κB-inducing signaling cascade downstream of the IL-1 type-I receptor.","method":"Yeast two-hybrid (Traf2 binding), expression of dominant-negative kinase mutants in cells, NF-κB reporter assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — dominant-negative mutagenesis of kinase combined with reporter assays, multiple receptor systems tested, widely replicated concept","pmids":["9020361"],"is_preprint":false},{"year":1998,"finding":"IL-1α and IL-1β are produced by resident macrophages within human islets of Langerhans in response to TNF + LPS + IFN-γ stimulation. Endogenously released IL-1 drives iNOS expression and nitric oxide production in beta cells, resulting in inhibition of glucose-stimulated insulin secretion. The IL-1 receptor antagonist protein (IRAP) blocked these effects, demonstrating a paracrine IL-1 → iNOS → NO → insulin secretion inhibition axis.","method":"RT-PCR for IL-1α/β mRNA, immunohistochemical colocalization with CD69 macrophage marker, IL-1Ra blockade, aminoguanidine (iNOS inhibitor), nitrite assay, insulin secretion assay","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (molecular, pharmacological, cellular), mechanistic pathway established with specific inhibitors","pmids":["9691088"],"is_preprint":false},{"year":1999,"finding":"The cytoplasmic domain of IL-1R type I (IL-1Rcd) directly associates with RhoA and Rac-1 (but not p21Ras). IL-1 stimulation rapidly activates nucleotide exchange on RhoA and induces actin stress fiber formation in a Rho-dependent manner. RhoA association with IL-1Rcd is required for IL-1-directed NF-κB/IL-6 transcriptional activation and for IL-1R-associated MBP kinase activity.","method":"GST pulldown of RhoA/Rac-1 from cell extracts, coimmunoprecipitation with anti-IL-1R antibody, C3 transferase ADP-ribosylation assay, dominant-inhibitory RhoA transfection, reporter gene (IL-6 promoter), gel kinase assay","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical interaction (GST pulldown + Co-IP) combined with functional mutagenesis and kinase assays in a single study","pmids":["10359565"],"is_preprint":false},{"year":2000,"finding":"IRAK (IL-1 receptor-associated kinase) is activated by LPS in macrophages through a TLR4-dependent mechanism. IRAK-deficient macrophages are resistant to LPS-induced signaling and show impaired TNF-α production. IRAK-deficient mice withstand lethal LPS challenge, establishing IRAK as a critical signaling mediator shared between the IL-1/IL-18 receptor and TLR pathways.","method":"IRAK knockout macrophages, LPS stimulation, signaling cascade analysis, TNF-α production assay, in vivo LPS lethality model","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple cellular and in vivo phenotypic readouts, functionally establishes pathway position","pmids":["10754329"],"is_preprint":false},{"year":2002,"finding":"Leishmania major activates IL-1α promoter activity and mRNA expression in macrophages through a MyD88-dependent pathway. Dominant-negative MyD88 transfection and peritoneal macrophages from MyD88−/− mice both showed inhibited IL-1α promoter/mRNA responses to L. major. Despite mRNA induction, no IL-1α protein was detectable in cell lysates or supernatants, indicating additional anti-inflammatory pathways suppress IL-1α translation.","method":"Cytokine promoter-luciferase reporter transfection, dominant-negative MyD88 expression, MyD88−/− knockout macrophages, RT-PCR, ELISA","journal":"Microbes and Infection","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout and dominant-negative plus reporter assays, single lab, establishes MyD88 as upstream regulator of IL-1α transcription","pmids":["12270723"],"is_preprint":false},{"year":2005,"finding":"TNF induces stromal cell expression of IL-1 and IL-1 receptor type I (IL-1RI). IL-1 (both α and β forms) then mediates TNF-induced RANKL expression by bone marrow stromal cells and directly stimulates osteoclast precursor differentiation via p38 MAPK, accounting for ~50% of TNF-induced osteoclastogenesis. IL-1Ra or IL-1RI deficiency abolished this TNF→IL-1→RANKL pathway.","method":"IL-1Ra treatment, IL-1RI-knockout stromal cells, co-culture osteoclastogenesis assay, in vivo TNF administration to IL-1RI-KO mice, p38 MAPK inhibition","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout combined with pharmacological blockade and in vivo validation, mechanistic pathway established with multiple orthogonal approaches","pmids":["15668736"],"is_preprint":false},{"year":2005,"finding":"Central IL-1 receptor signaling via hypothalamic IL-1RI normally restrains bone resorption; IL-1RI-deficient mice and mice with CNS-targeted IL-1Ra overexpression (under GFAP promoter) both exhibited low bone mass and impaired bone growth characterized by doubled osteoclast number. This phenotype occurred without changes in testosterone or corticosterone, suggesting a neural pathway distinct from the HPA and gonadal axes.","method":"IL-1RI knockout mice, CNS-targeted IL-1Ra transgenic mice (GFAP promoter), bone histomorphometry, serum hormone measurements","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent genetic mouse models with convergent bone phenotype, establishing central IL-1R signaling role in bone homeostasis","pmids":["16126903"],"is_preprint":false},{"year":2007,"finding":"Intratesticular administration of IL-1α in adult rats disrupted blood-testis barrier (BTB) integrity and caused Sertoli-germ cell adhesion loss without altering steady-state levels of BTB proteins (OCLN, CLDN1, F11R, TJP1, CDH2). Instead, IL-1α altered the subcellular localizations of OCLN, F11R, and TJP1 away from cell-cell contact sites and disrupted the orderly arrangement of filamentous actin at the BTB and apical ectoplasmic specialization.","method":"Intratesticular IL-1α injection, inulin-FITC BTB integrity assay, Western blotting, immunofluorescence localization, phalloidin staining for F-actin","journal":"Biology of Reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo functional experiment with multiple molecular readouts establishing actin cytoskeleton as IL-1α's primary cellular target in BTB regulation, single lab","pmids":["18057314"],"is_preprint":false},{"year":2007,"finding":"The SNP at position +4845 of IL1A (G/T, encoding Ala or Ser at amino acid 114 of precursor IL-1α) affects enzymatic efficiency of calpain in cleaving precursor IL-1α. A 100-fold higher calpain concentration was required to process pre-IL-1α containing Ala (GG genotype, enriched in SSc patients) compared to Ser (TT genotype). The -889 C/T promoter SNP did not significantly affect transcriptional activity in fibroblasts.","method":"Luciferase reporter assay for promoter SNP, Western blotting after calpain titration of cell lysates from fibroblasts with defined +4845 genotypes","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic processing assay with defined genetic variants, single lab, mechanistically links SNP to calpain cleavage efficiency","pmids":["17440718"],"is_preprint":false},{"year":2011,"finding":"Listeria-infected epithelial cells release IL-1α, which signals neighboring keratinocytes in a paracrine manner through the IL-1 receptor to upregulate S100A8/A9 expression and confer resistance to bacterial invasion. shRNA knockdown of S100A8/A9 reversed IL-1α-mediated resistance, establishing the IL-1α → IL-1R → S100A8/A9 axis as the mechanism of keratinocyte antibacterial defense.","method":"L. monocytogenes infection assay, conditioned media transfer, IL-1R antagonist blockade, shRNA knockdown of S100A8/A9, intracellular bacterial quantification","journal":"Mucosal Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal interventions (receptor antagonist + shRNA knockdown) with functional bacterial invasion readout, mechanistic pathway established","pmids":["22031183"],"is_preprint":false},{"year":2012,"finding":"Crystal structure of the IL-1β–IL-1RI–IL-1RAcP signaling complex was determined, revealing that IL-1-type cytokines initiate signaling by binding a primary receptor that recruits an accessory protein to form a signaling-competent heterotrimeric complex, and establishing an evolutionary relationship between IL-1R and fibroblast growth factor receptor family.","method":"X-ray crystallography of the ternary IL-1β/IL-1RI/IL-1RAcP complex","journal":"Nature Structural & Molecular Biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure of the complete signaling complex, definitive structural mechanism","pmids":["22426547"],"is_preprint":false},{"year":2015,"finding":"mTOR/TORC1 selectively promotes translation of membrane-bound IL-1α in senescent cells. Rapamycin suppressed IL-1α translation (but not mRNA levels), thereby reducing NF-κB transcriptional activity and downstream SASP cytokine secretion (IL-6 and others). Exogenous IL-1α restored IL-6 secretion in rapamycin-treated senescent cells, establishing IL-1α as a key upstream regulator of the SASP through NF-κB.","method":"Rapamycin treatment, IL-1α protein/mRNA quantification, cytokine ELISA, NF-κB reporter assay, exogenous IL-1α rescue experiment, in vivo tumor growth assay with senescent fibroblasts","journal":"Nature Cell Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological and rescue experiments with multiple orthogonal readouts establishing mTOR→IL-1α translation→NF-κB→SASP pathway","pmids":["26147250"],"is_preprint":false},{"year":2022,"finding":"Aging bone marrow myeloid cells produce increasing amounts of IL-1α and IL-1β in steady state; exposure to microbial products (TLR4/TLR8 ligands from gut microbiota) drives this IL-1 production. Signaling through IL-1R1 on hematopoietic stem cells drives myeloid-biased aging phenotype. IL-1R1 knockout mice, germ-free mice, antibiotic treatment, or pharmacologic IL-1 blockade all reversed myeloid-biased HSC output, establishing the microbiome/IL-1/IL-1R1 axis as a driver of HSC inflammaging.","method":"IL-1R1 knockout mice, germ-free mice, antibiotic treatment, in vitro cytokine stimulation, bone marrow transplantation, transcriptomic analysis of HSCs","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple independent genetic and pharmacological interventions with convergent functional readout in vivo, mechanistic pathway from microbiome to IL-1 to HSC aging established","pmids":["34525198"],"is_preprint":false},{"year":2023,"finding":"IL-1α (and IL-1β) signaling through IL-1R1 drives clonal expansion of Tet2+/− hematopoietic stem and progenitor cells (HSPCs) during aging. IL-1α treatment increased Tet2+/− HSPC cell cycle progression, multilineage differentiation, and repopulation capacity relative to wild-type HPSCs. Genetic deletion of IL-1R1 in Tet2+/− HSPCs or pharmacologic IL-1 inhibition impaired Tet2+/− clonal expansion, establishing the IL-1/IL-1R1 axis as a therapeutically targetable driver of TET2-mutant clonal hematopoiesis.","method":"Bone marrow transplantation, genetic mosaicism mouse model (HSC-SCL-Cre-ERT; Tet2+/flox), IL-1α administration, IL-1R1 conditional knockout, pharmacologic IL-1 inhibition, cell cycle analysis, transcriptomic analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacologic interventions with in vivo functional readouts, replicated across approaches","pmids":["36379023"],"is_preprint":false},{"year":2023,"finding":"A de novo gain-of-function missense variant in IL-1R1 (p.Lys131Glu) disrupts binding of the antagonist IL-1Ra but not IL-1α or IL-1β, resulting in unopposed IL-1 signaling and autoinflammation (CRMO). Mice with the homologous mutation showed hyperinflammation and pathological osteoclastogenesis. This structural insight was used to design an IL-1 therapeutic that traps IL-1α and IL-1β but spares IL-1Ra.","method":"Patient PBMC transcriptomics, mutant mouse model, binding assays for IL-1Ra/IL-1α/IL-1β to mutant receptor, collagen antibody-induced arthritis model, structure-guided drug design","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — combined patient genetics, functional receptor binding assays, in vivo mouse model, and structure-guided therapeutic design","pmids":["37315560"],"is_preprint":false},{"year":2024,"finding":"Age-associated decline of DNA methyltransferase 3A (DNMT3A) in hematopoietic myeloid progenitor-like cells enhances IL-1α production. These cells accumulate in lung tumors with aging and drive emergency myelopoiesis via IL-1α. Disrupting IL-1R1 signaling early in tumor development normalized myelopoiesis and slowed lung, colonic, and pancreatic tumor growth.","method":"Hematopoietic aging chimera experiments, DNMT3A loss-of-function, IL-1α quantification, IL-1R1 genetic disruption, tumor growth assays in multiple cancer models, human tumor single-cell analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic interventions, multiple tumor models, mechanistic link from DNMT3A → IL-1α → myelopoiesis → tumor progression established","pmids":["39236155"],"is_preprint":false}],"current_model":"IL-1α is a dual-compartment cytokine: the membrane-associated/nuclear precursor form is constitutively expressed in epithelial and myeloid cells and acts as a damage-associated alarmin (DAMP) that is released upon necrosis, while its mTOR-regulated translation drives NF-κB-dependent SASP in senescent cells; upon binding IL-1R1 (a three-immunoglobulin-domain receptor that recruits IL-1RAcP to form a signaling-competent heterotrimer), IL-1α activates downstream signaling via IRAK and NIK kinases leading to NF-κB and MAPK pathway activation, with RhoA physically associating with the IL-1R cytoplasmic domain to amplify cytoskeletal and transcriptional responses; IL-1α also regulates tissue-specific processes including blood-testis barrier restructuring via actin cytoskeletal reorganization, keratinocyte antibacterial defense through paracrine S100A8/A9 induction, thymocyte CD25 induction and T cell lineage commitment, bone resorption restraint via central hypothalamic IL-1R1 signaling, and hematopoietic stem cell aging and clonal hematopoiesis expansion through IL-1R1 on HSPCs."},"narrative":{"mechanistic_narrative":"IL-1α is a pleiotropic pro-inflammatory cytokine whose precursor is constitutively expressed in epithelial and myeloid cells and which signals through the type I IL-1 receptor (IL-1R1) to drive NF-κB- and MAPK-dependent inflammatory programs [PMID:3258334, PMID:22031183]. The receptor, a three-immunoglobulin-domain protein that binds IL-1α and IL-1β indistinguishably, initiates signaling by recruiting the accessory protein IL-1RAcP to assemble a signaling-competent heterotrimeric complex [PMID:2969618, PMID:22426547]. Downstream, the IL-1R1 cytoplasmic domain engages the kinases IRAK and NIK to activate NF-κB, while directly associating with RhoA and Rac-1 to couple receptor engagement to actin stress fiber formation and amplified NF-κB/IL-6 transcription [PMID:9020361, PMID:10359565, PMID:10754329]. IL-1α expression and processing are controlled at multiple levels: keratinocyte transcription is constitutive and modulated by LPS, UV, and differentiation state [PMID:3258334]; calpain cleaves the precursor with efficiency that depends on a coding polymorphism [PMID:17440718]; and mTOR/TORC1 selectively promotes IL-1α translation in senescent cells to drive NF-κB-dependent SASP cytokine secretion [PMID:26147250]. Through IL-1R1, IL-1α governs diverse tissue processes including paracrine S100A8/A9-mediated keratinocyte antibacterial defense [PMID:22031183], blood-testis barrier restructuring via actin reorganization [PMID:18057314], thymocyte CD25 induction and T cell lineage commitment [PMID:7541554], central hypothalamic restraint of bone resorption [PMID:16126903], and TNF-induced RANKL-dependent osteoclastogenesis [PMID:15668736]. In aging, myeloid-derived IL-1α driven by microbial signals and DNMT3A decline acts on IL-1R1 on hematopoietic stem/progenitor cells to promote myeloid-biased aging, clonal expansion of TET2-mutant clones, emergency myelopoiesis, and tumor progression [PMID:34525198, PMID:36379023, PMID:39236155]. A gain-of-function IL-1R1 variant that abolishes IL-1Ra binding causes the autoinflammatory disease CRMO, underscoring the pathological consequence of unopposed IL-1 signaling [PMID:37315560].","teleology":[{"year":1988,"claim":"Establishing the molecular identity of the IL-1 receptor defined how IL-1α and IL-1β share a single signaling entry point.","evidence":"cDNA expression cloning from mouse T cells with receptor-binding validation","pmids":["2969618"],"confidence":"High","gaps":["Did not resolve how the receptor distinguishes agonist from antagonist","Cytoplasmic signaling machinery not yet defined","No accessory subunit identified"]},{"year":1988,"claim":"Demonstrating constitutive, condition-responsive IL-1α expression in keratinocytes established epithelial cells as a source of IL-1α independent of IL-1β.","evidence":"Northern blotting and IL-1 bioassay in keratinocyte culture under defined Ca²⁺ and LPS/UV conditions","pmids":["3258334"],"confidence":"Medium","gaps":["Mechanism linking differentiation state to expression unresolved","Did not define release or signaling consequences"]},{"year":1989,"claim":"Chronic in vivo IL-1α exposure was shown to drive selective skeletal muscle protein catabolism, defining a systemic catabolic action.","evidence":"Chronic cytokine administration in rats with protein fractionation and muscle mRNA Northern blotting","pmids":["2784290"],"confidence":"Medium","gaps":["Receptor/signaling pathway mediating muscle wasting not identified","Tissue selectivity mechanism unknown"]},{"year":1990,"claim":"Internalization of the IL-1α–receptor complex into nuclei and the regulation of IL-1β bioactivity by α2-macroglobulin sequestration revealed post-binding control of IL-1 action.","evidence":"125I-IL-1 internalization with EM autoradiography and nuclear fractionation; native PAGE binding/release assays with thioredoxin and bioassays","pmids":["2137488","1700994"],"confidence":"Medium","gaps":["Functional role of nuclear receptor translocation not established","Physiological relevance of α2M sequestration in vivo unresolved"]},{"year":1991,"claim":"Chromosomal mapping placed IL1A, IL1B, and IL1R1 in proximity on human 2q, framing the genomic organization of the IL-1 system.","evidence":"Hybrid cell segregation, in situ hybridization, and RFLP analysis in human and mouse","pmids":["1672292"],"confidence":"Medium","gaps":["No functional consequence of genomic clustering established","Regulatory linkage not addressed"]},{"year":1995,"claim":"Identifying IL-1α as necessary for thymocyte CD25 induction and CD4/CD8 differentiation extended IL-1α function to T cell development.","evidence":"Thymus reconstitution in irradiated mice with flow cytometry and cytokine neutralization epistasis","pmids":["7541554"],"confidence":"Medium","gaps":["Did not separate IL-1α from TNF-α requirement molecularly","Receptor-level signaling in thymocytes not dissected"]},{"year":1997,"claim":"Placing NIK in the IL-1-to-NF-κB cascade identified a shared kinase node converging IL-1, TNF, and CD95 signaling onto NF-κB.","evidence":"Yeast two-hybrid and dominant-negative kinase expression with NF-κB reporter assays","pmids":["9020361"],"confidence":"High","gaps":["Precise position relative to IRAK not resolved here","Endogenous requirement not tested genetically in this study"]},{"year":1998,"claim":"Demonstrating a paracrine IL-1 → iNOS → NO axis in pancreatic islets established IL-1α as a driver of beta-cell dysfunction.","evidence":"RT-PCR, macrophage colocalization, IL-1Ra blockade, iNOS inhibition, and insulin secretion assays in human islets","pmids":["9691088"],"confidence":"High","gaps":["Relative contribution of IL-1α vs IL-1β not separated","Long-term beta-cell fate not addressed"]},{"year":1999,"claim":"Discovery that the IL-1R cytoplasmic domain directly binds RhoA/Rac-1 connected receptor engagement to cytoskeletal remodeling and transcriptional output.","evidence":"GST pulldown, Co-IP, C3 transferase, dominant-inhibitory RhoA, IL-6 promoter reporter, and gel kinase assays","pmids":["10359565"],"confidence":"High","gaps":["Adaptor bridging receptor to RhoA not defined","Reciprocal in vivo validation absent"]},{"year":2000,"claim":"Genetic ablation of IRAK established it as an essential signaling mediator shared between IL-1/IL-18 and TLR pathways.","evidence":"IRAK knockout macrophages and in vivo LPS lethality model with TNF-α production readouts","pmids":["10754329"],"confidence":"High","gaps":["IL-1α-specific (vs IL-1β/TLR) requirement not isolated","Downstream substrate connections not mapped here"]},{"year":2002,"claim":"Linking IL-1α transcription to MyD88 revealed pathogen-driven upstream regulation while uncoupling mRNA induction from protein output.","evidence":"Promoter-luciferase reporter, dominant-negative MyD88, MyD88−/− macrophages, RT-PCR and ELISA after L. major infection","pmids":["12270723"],"confidence":"Medium","gaps":["Translational/processing block preventing protein accumulation not identified","Single pathogen context"]},{"year":2005,"claim":"Two studies defined IL-1's role in bone homeostasis: peripherally driving TNF-induced RANKL/osteoclastogenesis and centrally restraining bone resorption via hypothalamic IL-1R1.","evidence":"IL-1RI-knockout stromal cells, co-culture osteoclastogenesis, p38 inhibition, and CNS-targeted IL-1Ra transgenic mice with bone histomorphometry","pmids":["15668736","16126903"],"confidence":"High","gaps":["IL-1α vs IL-1β contribution to each arm not separated","Neural circuitry of central restraint undefined"]},{"year":2007,"claim":"Two studies established IL-1α's regulation of the blood-testis barrier via actin reorganization and a coding SNP controlling calpain processing efficiency.","evidence":"Intratesticular IL-1α injection with BTB integrity, immunolocalization, and phalloidin staining; calpain titration of fibroblast lysates with defined +4845 genotypes","pmids":["18057314","17440718"],"confidence":"Medium","gaps":["Signaling pathway from IL-1R1 to actin in Sertoli cells not mapped","Clinical impact of processing-efficiency SNP not functionally proven in vivo"]},{"year":2011,"claim":"Defining the IL-1α → IL-1R → S100A8/A9 paracrine axis established a mechanism for epithelial antibacterial defense.","evidence":"L. monocytogenes infection, conditioned media transfer, IL-1R antagonist, and S100A8/A9 shRNA knockdown with bacterial quantification","pmids":["22031183"],"confidence":"High","gaps":["Mode of IL-1α release from infected cells not defined","Generalizability beyond Listeria untested"]},{"year":2012,"claim":"The crystal structure of the IL-1β/IL-1RI/IL-1RAcP complex defined the heterotrimeric receptor assembly that initiates IL-1-type signaling.","evidence":"X-ray crystallography of the ternary signaling complex","pmids":["22426547"],"confidence":"High","gaps":["Structure solved with IL-1β rather than IL-1α","Cytoplasmic assembly of adaptors not captured"]},{"year":2015,"claim":"Identifying mTOR-dependent translational control of membrane IL-1α positioned IL-1α as the upstream NF-κB driver of the senescence-associated secretory phenotype.","evidence":"Rapamycin treatment with IL-1α protein/mRNA quantification, NF-κB reporter, cytokine ELISA, and exogenous IL-1α rescue in senescent fibroblasts","pmids":["26147250"],"confidence":"High","gaps":["Mechanism of selective IL-1α mRNA translation not resolved","In vivo SASP relevance only partially addressed"]},{"year":2022,"claim":"Defining the microbiome/IL-1/IL-1R1 axis established myeloid-derived IL-1α as a driver of hematopoietic stem cell inflammaging.","evidence":"IL-1R1 knockout, germ-free and antibiotic-treated mice, bone marrow transplantation, and HSC transcriptomics","pmids":["34525198"],"confidence":"High","gaps":["IL-1α vs IL-1β specific contribution not fully separated","Molecular events downstream of IL-1R1 in HSCs not detailed"]},{"year":2023,"claim":"Two studies established the IL-1/IL-1R1 axis as a driver of TET2-mutant clonal hematopoiesis and identified a CRMO-causing gain-of-function IL-1R1 variant that abolishes antagonist binding.","evidence":"Tet2+/− mosaic mouse models with IL-1α administration and IL-1R1 conditional knockout; patient genetics, mutant receptor binding assays, mouse arthritis model, and structure-guided drug design","pmids":["36379023","37315560"],"confidence":"High","gaps":["Whether IL-1α or IL-1β dominates clonal expansion not resolved","Human therapeutic efficacy of antagonist-sparing trap not yet clinically validated"]},{"year":2024,"claim":"Linking age-associated DNMT3A decline to IL-1α-driven emergency myelopoiesis connected hematopoietic aging to tumor progression across cancer types.","evidence":"Hematopoietic aging chimeras, DNMT3A loss-of-function, IL-1R1 genetic disruption, multiple tumor models, and human tumor single-cell analysis","pmids":["39236155"],"confidence":"High","gaps":["Mechanism by which DNMT3A loss enhances IL-1α specifically not detailed","Translation to human therapy not established"]},{"year":null,"claim":"How the distinct activities of IL-1α — nuclear/precursor alarmin functions, calpain-dependent processing, and receptor-mediated signaling — are integrated and differentiated from IL-1β at the cellular level remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Most in vivo studies do not separate IL-1α from IL-1β contributions","Functional role of nuclear IL-1α localization uncharacterized","Direct structure of the IL-1α (vs IL-1β) ternary receptor complex not in corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,16,17]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[16,18]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[18]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[16,19,22]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,9,10]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[18]}],"complexes":["IL-1α/IL-1R1/IL-1RAcP signaling complex"],"partners":["IL1R1","IL1RAP","RHOA","RAC1","IRAK1","MAP3K14","A2M"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01583","full_name":"Interleukin-1 alpha","aliases":["Hematopoietin-1"],"length_aa":271,"mass_kda":30.6,"function":"Cytokine constitutively present intracellularly in nearly all resting non-hematopoietic cells that plays an important role in inflammation and bridges the innate and adaptive immune systems (PubMed:26439902). After binding to its receptor IL1R1 together with its accessory protein IL1RAP, forms the high affinity interleukin-1 receptor complex (PubMed:17507369, PubMed:2950091). Signaling involves the recruitment of adapter molecules such as MYD88, IRAK1 or IRAK4 (PubMed:17507369). In turn, mediates the activation of NF-kappa-B and the three MAPK pathways p38, p42/p44 and JNK pathways (PubMed:14687581). Within the cell, acts as an alarmin and cell death results in its liberation in the extracellular space after disruption of the cell membrane to induce inflammation and alert the host to injury or damage (PubMed:15679580). In addition to its role as a danger signal, which occurs when the cytokine is passively released by cell necrosis, directly senses DNA damage and acts as a signal for genotoxic stress without loss of cell integrity (PubMed:26439902)","subcellular_location":"Nucleus; Cytoplasm; Secreted","url":"https://www.uniprot.org/uniprotkb/P01583/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL1A","classification":"Not Classified","n_dependent_lines":14,"n_total_lines":1208,"dependency_fraction":0.011589403973509934},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL1A","total_profiled":1310},"omim":[{"mim_id":"615296","title":"INTERLEUKIN 1 FAMILY, MEMBER 10; IL1F10","url":"https://www.omim.org/entry/615296"},{"mim_id":"614674","title":"PERIODIC FEVER, MENSTRUAL CYCLE-DEPENDENT","url":"https://www.omim.org/entry/614674"},{"mim_id":"611599","title":"MICRO RNA 206; MIR206","url":"https://www.omim.org/entry/611599"},{"mim_id":"610175","title":"MICRO RNA 130A; MIR130A","url":"https://www.omim.org/entry/610175"},{"mim_id":"609827","title":"PELLINO E3 UBIQUITIN PROTEIN LIGASE 3; PELI3","url":"https://www.omim.org/entry/609827"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"esophagus","ntpm":13.5},{"tissue":"testis","ntpm":9.7},{"tissue":"urinary bladder","ntpm":24.1}],"url":"https://www.proteinatlas.org/search/IL1A"},"hgnc":{"alias_symbol":["IL1F1","IL-1A","IL1-ALPHA"],"prev_symbol":["IL1"]},"alphafold":{"accession":"P01583","domains":[{"cath_id":"2.80.10.50","chopping":"124-266","consensus_level":"high","plddt":95.2813,"start":124,"end":266}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01583","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01583-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01583-F1-predicted_aligned_error_v6.png","plddt_mean":73.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL1A","jax_strain_url":"https://www.jax.org/strain/search?query=IL1A"},"sequence":{"accession":"P01583","fasta_url":"https://rest.uniprot.org/uniprotkb/P01583.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01583/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01583"}},"corpus_meta":[{"pmid":"29247995","id":"PMC_29247995","title":"Overview of the IL-1 family in innate inflammation and acquired immunity.","date":"2018","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29247995","citation_count":1437,"is_preprint":false},{"pmid":"9020361","id":"PMC_9020361","title":"MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9020361","citation_count":1121,"is_preprint":false},{"pmid":"26147250","id":"PMC_26147250","title":"MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.","date":"2015","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26147250","citation_count":922,"is_preprint":false},{"pmid":"16547218","id":"PMC_16547218","title":"The P2X7 receptor: a key player in IL-1 processing and release.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16547218","citation_count":871,"is_preprint":false},{"pmid":"2969618","id":"PMC_2969618","title":"cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily.","date":"1988","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2969618","citation_count":863,"is_preprint":false},{"pmid":"20081870","id":"PMC_20081870","title":"Disease-associated functions of IL-33: the new kid in the IL-1 family.","date":"2010","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20081870","citation_count":825,"is_preprint":false},{"pmid":"20086235","id":"PMC_20086235","title":"Interleukin-1 (IL-1) pathway.","date":"2010","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/20086235","citation_count":778,"is_preprint":false},{"pmid":"29880500","id":"PMC_29880500","title":"NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.","date":"2018","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/29880500","citation_count":723,"is_preprint":false},{"pmid":"20177398","id":"PMC_20177398","title":"IL-1 pathways in inflammation and human diseases.","date":"2010","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/20177398","citation_count":722,"is_preprint":false},{"pmid":"18613828","id":"PMC_18613828","title":"IL-1, IL-18, and IL-33 families of cytokines.","date":"2008","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18613828","citation_count":707,"is_preprint":false},{"pmid":"15668736","id":"PMC_15668736","title":"IL-1 mediates TNF-induced osteoclastogenesis.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15668736","citation_count":583,"is_preprint":false},{"pmid":"12220547","id":"PMC_12220547","title":"The balance between IL-1 and IL-1Ra in disease.","date":"2002","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12220547","citation_count":579,"is_preprint":false},{"pmid":"14989423","id":"PMC_14989423","title":"The IL-1 family and inflammatory diseases.","date":"2002","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/14989423","citation_count":502,"is_preprint":false},{"pmid":"2784290","id":"PMC_2784290","title":"Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins.","date":"1989","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/2784290","citation_count":312,"is_preprint":false},{"pmid":"28043870","id":"PMC_28043870","title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.","date":"2016","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28043870","citation_count":298,"is_preprint":false},{"pmid":"31515542","id":"PMC_31515542","title":"The IL-1 family of cytokines and receptors in rheumatic diseases.","date":"2019","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/31515542","citation_count":271,"is_preprint":false},{"pmid":"31281320","id":"PMC_31281320","title":"Structural Basis of IL-1 Family Cytokine Signaling.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31281320","citation_count":239,"is_preprint":false},{"pmid":"24422572","id":"PMC_24422572","title":"IL-1 blockade in autoinflammatory syndromes.","date":"2014","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24422572","citation_count":236,"is_preprint":false},{"pmid":"10754329","id":"PMC_10754329","title":"IL-1 receptor-associated kinase modulates host responsiveness to endotoxin.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10754329","citation_count":219,"is_preprint":false},{"pmid":"22764097","id":"PMC_22764097","title":"Caspase-1: is IL-1 just the tip of the ICEberg?","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22764097","citation_count":218,"is_preprint":false},{"pmid":"9691088","id":"PMC_9691088","title":"IL-1 produced and released endogenously within human islets inhibits beta cell function.","date":"1998","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9691088","citation_count":211,"is_preprint":false},{"pmid":"30528824","id":"PMC_30528824","title":"The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30528824","citation_count":199,"is_preprint":false},{"pmid":"23195532","id":"PMC_23195532","title":"IL-1 receptor 2 (IL-1R2) and its role in immune regulation.","date":"2012","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23195532","citation_count":198,"is_preprint":false},{"pmid":"24734023","id":"PMC_24734023","title":"The role IL-1 in tumor-mediated angiogenesis.","date":"2014","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24734023","citation_count":190,"is_preprint":false},{"pmid":"24659539","id":"PMC_24659539","title":"LPS and IL-1 differentially activate mouse and human astrocytes: role of CD14.","date":"2014","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/24659539","citation_count":174,"is_preprint":false},{"pmid":"2137488","id":"PMC_2137488","title":"IL-1 and its receptor are translocated to the nucleus.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2137488","citation_count":171,"is_preprint":false},{"pmid":"9917875","id":"PMC_9917875","title":"Sleep. A physiologic role for IL-1 beta and TNF-alpha.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9917875","citation_count":161,"is_preprint":false},{"pmid":"24829146","id":"PMC_24829146","title":"The TLR and IL-1 signalling network at a glance.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/24829146","citation_count":160,"is_preprint":false},{"pmid":"15251132","id":"PMC_15251132","title":"Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.","date":"2004","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15251132","citation_count":154,"is_preprint":false},{"pmid":"15110792","id":"PMC_15110792","title":"T1/ST2--an IL-1 receptor-like modulator of immune responses.","date":"2004","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15110792","citation_count":146,"is_preprint":false},{"pmid":"22925041","id":"PMC_22925041","title":"Targeting IL-1 in depression.","date":"2012","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/22925041","citation_count":138,"is_preprint":false},{"pmid":"25216251","id":"PMC_25216251","title":"IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25216251","citation_count":136,"is_preprint":false},{"pmid":"17097645","id":"PMC_17097645","title":"IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?","date":"2006","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17097645","citation_count":134,"is_preprint":false},{"pmid":"36379023","id":"PMC_36379023","title":"Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36379023","citation_count":133,"is_preprint":false},{"pmid":"34525198","id":"PMC_34525198","title":"IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34525198","citation_count":133,"is_preprint":false},{"pmid":"19965648","id":"PMC_19965648","title":"Regulating human Th17 cells via differential expression of IL-1 receptor.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19965648","citation_count":124,"is_preprint":false},{"pmid":"30930244","id":"PMC_30930244","title":"IL-1 and TNFα Contribute to the Inflammatory Niche to Enhance Alveolar Regeneration.","date":"2019","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30930244","citation_count":122,"is_preprint":false},{"pmid":"23874332","id":"PMC_23874332","title":"IL-1 and T Helper Immune Responses.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23874332","citation_count":122,"is_preprint":false},{"pmid":"7541554","id":"PMC_7541554","title":"Requirement for TNF-alpha and IL-1 alpha in fetal thymocyte commitment and differentiation.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7541554","citation_count":120,"is_preprint":false},{"pmid":"7964161","id":"PMC_7964161","title":"The IL-1 receptor signaling pathway.","date":"1994","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/7964161","citation_count":118,"is_preprint":false},{"pmid":"31249675","id":"PMC_31249675","title":"IL-1 in osteoarthritis: time for a critical review of the literature.","date":"2019","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/31249675","citation_count":118,"is_preprint":false},{"pmid":"3258334","id":"PMC_3258334","title":"The expression and modulation of IL-1 alpha in murine keratinocytes.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3258334","citation_count":117,"is_preprint":false},{"pmid":"10359565","id":"PMC_10359565","title":"The IL-1 receptor and Rho directly associate to drive cell activation in inflammation.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10359565","citation_count":117,"is_preprint":false},{"pmid":"39236155","id":"PMC_39236155","title":"Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis.","date":"2024","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/39236155","citation_count":113,"is_preprint":false},{"pmid":"29665983","id":"PMC_29665983","title":"IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies.","date":"2018","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29665983","citation_count":113,"is_preprint":false},{"pmid":"32663626","id":"PMC_32663626","title":"The IL-1 family cytokines and receptors in autoimmune diseases.","date":"2020","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32663626","citation_count":100,"is_preprint":false},{"pmid":"22426547","id":"PMC_22426547","title":"Structure of the activating IL-1 receptor signaling complex.","date":"2012","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22426547","citation_count":98,"is_preprint":false},{"pmid":"22631445","id":"PMC_22631445","title":"Inflammasome activation of IL-1 family mediators in response to cutaneous photodamage.","date":"2012","source":"Photochemistry and photobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22631445","citation_count":85,"is_preprint":false},{"pmid":"32060884","id":"PMC_32060884","title":"IL-1 Signaling in Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060884","citation_count":83,"is_preprint":false},{"pmid":"27647856","id":"PMC_27647856","title":"IL-1 Inhibition and Vascular Function in CKD.","date":"2016","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/27647856","citation_count":79,"is_preprint":false},{"pmid":"15850931","id":"PMC_15850931","title":"Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis.","date":"2005","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/15850931","citation_count":79,"is_preprint":false},{"pmid":"24239046","id":"PMC_24239046","title":"Negative regulatory receptors of the IL-1 family.","date":"2013","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24239046","citation_count":77,"is_preprint":false},{"pmid":"32682440","id":"PMC_32682440","title":"Blocking IL-1 to prevent respiratory failure in COVID-19.","date":"2020","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32682440","citation_count":76,"is_preprint":false},{"pmid":"23577011","id":"PMC_23577011","title":"Autophagy and IL-1 Family Cytokines.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23577011","citation_count":76,"is_preprint":false},{"pmid":"1672292","id":"PMC_1672292","title":"Chromosomal location of murine and human IL-1 receptor genes.","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1672292","citation_count":71,"is_preprint":false},{"pmid":"32758110","id":"PMC_32758110","title":"IL-1 Superfamily Members and Periodontal Diseases.","date":"2020","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/32758110","citation_count":70,"is_preprint":false},{"pmid":"28569730","id":"PMC_28569730","title":"Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28569730","citation_count":70,"is_preprint":false},{"pmid":"35003136","id":"PMC_35003136","title":"The Immunological Impact of IL-1 Family Cytokines on the Epidermal Barrier.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35003136","citation_count":70,"is_preprint":false},{"pmid":"18057314","id":"PMC_18057314","title":"Interleukin 1 alpha (IL1A) is a novel regulator of the blood-testis barrier in the rat.","date":"2007","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/18057314","citation_count":70,"is_preprint":false},{"pmid":"2784458","id":"PMC_2784458","title":"Rabbit IL-1. Cloning, expression, biologic properties, and transcription during endotoxemia.","date":"1989","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2784458","citation_count":67,"is_preprint":false},{"pmid":"11937546","id":"PMC_11937546","title":"Regulation of IL-1 receptor-associated kinases by lipopolysaccharide.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11937546","citation_count":67,"is_preprint":false},{"pmid":"15268666","id":"PMC_15268666","title":"Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.","date":"2004","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15268666","citation_count":64,"is_preprint":false},{"pmid":"29198612","id":"PMC_29198612","title":"IL-1 family cytokines in cardiovascular disease.","date":"2017","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29198612","citation_count":63,"is_preprint":false},{"pmid":"33796114","id":"PMC_33796114","title":"IL-1 Family Antagonists in Mouse and Human Skin Inflammation.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33796114","citation_count":63,"is_preprint":false},{"pmid":"10589368","id":"PMC_10589368","title":"TNF alpha and IL-1 beta are separate targets in chronic arthritis.","date":"1999","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/10589368","citation_count":62,"is_preprint":false},{"pmid":"37315560","id":"PMC_37315560","title":"Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/37315560","citation_count":61,"is_preprint":false},{"pmid":"12270723","id":"PMC_12270723","title":"Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway.","date":"2002","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/12270723","citation_count":59,"is_preprint":false},{"pmid":"29272514","id":"PMC_29272514","title":"The role of IL-1 in gout: from bench to bedside.","date":"2018","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29272514","citation_count":58,"is_preprint":false},{"pmid":"23481102","id":"PMC_23481102","title":"IL-1 and EGF regulate expression of genes important in inflammation and cancer.","date":"2013","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/23481102","citation_count":56,"is_preprint":false},{"pmid":"16126903","id":"PMC_16126903","title":"Central IL-1 receptor signaling regulates bone growth and mass.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16126903","citation_count":55,"is_preprint":false},{"pmid":"34844039","id":"PMC_34844039","title":"IL-1 family cytokines as drivers and inhibitors of trained immunity.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/34844039","citation_count":53,"is_preprint":false},{"pmid":"12528118","id":"PMC_12528118","title":"Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population.","date":"2003","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/12528118","citation_count":53,"is_preprint":false},{"pmid":"1700994","id":"PMC_1700994","title":"Binding of IL-1 beta to alpha-macroglobulins and release by thioredoxin.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1700994","citation_count":53,"is_preprint":false},{"pmid":"25336714","id":"PMC_25336714","title":"Association between endometriosis and the interleukin 1A (IL1A) locus.","date":"2014","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25336714","citation_count":52,"is_preprint":false},{"pmid":"35462264","id":"PMC_35462264","title":"The IL-1 cytokine family as custodians of barrier immunity.","date":"2022","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/35462264","citation_count":50,"is_preprint":false},{"pmid":"35580824","id":"PMC_35580824","title":"The IL-1 family in tumorigenesis and antitumor immunity.","date":"2022","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/35580824","citation_count":49,"is_preprint":false},{"pmid":"28499891","id":"PMC_28499891","title":"SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes.","date":"2017","source":"Joint bone spine","url":"https://pubmed.ncbi.nlm.nih.gov/28499891","citation_count":49,"is_preprint":false},{"pmid":"33530653","id":"PMC_33530653","title":"Therapeutic Strategies for Targeting IL-1 in Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33530653","citation_count":49,"is_preprint":false},{"pmid":"12752325","id":"PMC_12752325","title":"The IL1A genotype is associated with nasal polyposis in asthmatic adults.","date":"2003","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/12752325","citation_count":47,"is_preprint":false},{"pmid":"27168953","id":"PMC_27168953","title":"Inflammasome, IL-1 and inflammation in ozone-induced lung injury.","date":"2016","source":"American journal of clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27168953","citation_count":46,"is_preprint":false},{"pmid":"27356916","id":"PMC_27356916","title":"Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement.","date":"2016","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27356916","citation_count":46,"is_preprint":false},{"pmid":"9159234","id":"PMC_9159234","title":"Structure-function relationship in the IL-1 family.","date":"1996","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/9159234","citation_count":45,"is_preprint":false},{"pmid":"29656546","id":"PMC_29656546","title":"A Guide to IL-1 family cytokines in adjuvanticity.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/29656546","citation_count":44,"is_preprint":false},{"pmid":"27826753","id":"PMC_27826753","title":"Intracellular interleukin (IL)-1 family cytokine processing enzyme.","date":"2016","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/27826753","citation_count":44,"is_preprint":false},{"pmid":"24272484","id":"PMC_24272484","title":"Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.","date":"2013","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24272484","citation_count":44,"is_preprint":false},{"pmid":"32204562","id":"PMC_32204562","title":"Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review.","date":"2020","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/32204562","citation_count":43,"is_preprint":false},{"pmid":"28798075","id":"PMC_28798075","title":"Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations.","date":"2017","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/28798075","citation_count":41,"is_preprint":false},{"pmid":"28522598","id":"PMC_28522598","title":"Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment.","date":"2017","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/28522598","citation_count":40,"is_preprint":false},{"pmid":"9836379","id":"PMC_9836379","title":"Treatment of rheumatoid arthritis with IL-1 inhibitors.","date":"1998","source":"Springer seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/9836379","citation_count":40,"is_preprint":false},{"pmid":"33643264","id":"PMC_33643264","title":"Role for IL-1 Family Cytokines in Fungal Infections.","date":"2021","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33643264","citation_count":39,"is_preprint":false},{"pmid":"22312160","id":"PMC_22312160","title":"Association between the IL-1 family gene cluster and spondyloarthritis.","date":"2012","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22312160","citation_count":39,"is_preprint":false},{"pmid":"17440718","id":"PMC_17440718","title":"Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity.","date":"2007","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17440718","citation_count":39,"is_preprint":false},{"pmid":"22031183","id":"PMC_22031183","title":"IL-1 receptor regulates S100A8/A9-dependent keratinocyte resistance to bacterial invasion.","date":"2011","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22031183","citation_count":38,"is_preprint":false},{"pmid":"36613465","id":"PMC_36613465","title":"The IL-1 Family and Its Role in Atherosclerosis.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36613465","citation_count":36,"is_preprint":false},{"pmid":"30470512","id":"PMC_30470512","title":"Potential roles of IL-1 subfamily members in glycolysis in disease.","date":"2018","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30470512","citation_count":35,"is_preprint":false},{"pmid":"24690566","id":"PMC_24690566","title":"The IL-1 family in fish: swimming through the muddy waters of inflammasome evolution.","date":"2014","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24690566","citation_count":35,"is_preprint":false},{"pmid":"20414049","id":"PMC_20414049","title":"IL-1 and Allergy.","date":"2010","source":"Allergology international : official journal of the Japanese Society of Allergology","url":"https://pubmed.ncbi.nlm.nih.gov/20414049","citation_count":34,"is_preprint":false},{"pmid":"30595799","id":"PMC_30595799","title":"Tryptophan Photoproduct FICZ Upregulates IL1A, IL1B, and IL6 Expression via Oxidative Stress in Keratinocytes.","date":"2018","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/30595799","citation_count":32,"is_preprint":false},{"pmid":"17021861","id":"PMC_17021861","title":"IL-1 Receptor antagonist as a positional candidate gene in a murine model of allergic asthma.","date":"2006","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17021861","citation_count":32,"is_preprint":false},{"pmid":"41087719","id":"PMC_41087719","title":"IL-1 family cytokines in inflammation and immunity.","date":"2025","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41087719","citation_count":31,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45080,"output_tokens":6461,"usd":0.116078,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15855,"output_tokens":5603,"usd":0.109675,"stage2_stop_reason":"end_turn"},"total_usd":0.225753,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"The IL-1 receptor was cloned by direct expression strategy from mouse T cells; the receptor binds both IL-1α and IL-1β, has an extracellular domain of 319 amino acids composed of three immunoglobulin-like domains, and a cytoplasmic domain of 217 amino acids. The cloned receptor product binds IL-1α and IL-1β indistinguishably from the native T cell IL-1R.\",\n      \"method\": \"cDNA expression cloning, receptor-binding assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct cDNA expression cloning with functional binding validation, foundational study\",\n      \"pmids\": [\"2969618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Murine keratinocytes constitutively express IL-1α mRNA (but not IL-1β mRNA). LPS exposure increased IL-1α mRNA >10-fold with a sixfold increase in secreted IL-1 activity. UV irradiation modulated IL-1α expression in a dose-dependent manner. IL-1α expression decreased with terminal keratinocyte differentiation (high Ca²⁺) and increased with undifferentiated state (low Ca²⁺).\",\n      \"method\": \"Northern blotting, IL-1 bioassay, keratinocyte culture under defined Ca²⁺ conditions\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA and bioactivity measurements, single lab, multiple conditions tested\",\n      \"pmids\": [\"3258334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Chronic in vivo administration of IL-1α produced protein wasting with accelerated peripheral skeletal muscle protein loss while preserving liver protein content, a pattern distinct from simple caloric restriction. Decrease in skeletal muscle protein was accompanied by coordinate decreases in mRNAs for myosin heavy chain, myosin light chain, actin, and ribosomal RNA subunits.\",\n      \"method\": \"In vivo chronic cytokine administration in rats, protein fractionation, Northern blotting for muscle mRNAs\",\n      \"journal\": \"American Journal of Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo functional experiment with molecular readouts, single lab\",\n      \"pmids\": [\"2784290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Internalized IL-1α remains bound to its receptor intracellularly for at least 4 hours without degradation, and accumulates in purified nuclei as an IL-1–receptor complex. No IL-1 receptors were detected in untreated nuclei, suggesting IL-1-driven translocation of the cell surface IL-1R complex to the nucleus. This internalization correlated with IL-1 signal transduction events required for growth factor production.\",\n      \"method\": \"125I-IL-1α internalization, electron microscope autoradiography, nuclear fractionation, receptor-binding in isolated nuclei\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by EM autoradiography and fractionation with functional correlation, single lab\",\n      \"pmids\": [\"2137488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"IL-1β binds to human alpha-2-macroglobulin (H-α2M) forming a complex in a pH- and divalent cation-dependent (Zn²⁺, Cd²⁺, Cu²⁺, Ni²⁺) manner. H-α2M-bound IL-1β is partially biologically inactive; reduced thioredoxin releases bound IL-1β and restores IL-1-like bioactivity. Binding requires histidyl residues in H-α2M.\",\n      \"method\": \"125I-IL-1β binding assay, native PAGE, competition assay, thioredoxin release assay, two independent bioassays\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and release experiments with functional bioassay validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"1700994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The human IL-1R1 gene was mapped to chromosome 2q12, near the IL-1α and IL-1β loci at 2q13–2q21. The murine Il-1r1 gene was mapped to chromosome 1, showing synteny with human chromosome 2 but separated from the murine IL-1 genes on chromosome 2.\",\n      \"method\": \"Rodent-human hybrid cell segregation analysis, chromosomal in situ hybridization, restriction fragment length polymorphism analysis in interspecific backcrosses\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct chromosomal mapping by multiple methods, single study\",\n      \"pmids\": [\"1672292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TNF-α and IL-1α, produced within the thymic microenvironment, are each necessary for early thymocyte maturation and CD4+CD8+ differentiation. Either cytokine induced CD25 expression on early immature thymocytes in a thymus reconstitution assay; absence of both (or either) blocked further T cell lineage commitment.\",\n      \"method\": \"Thymus reconstitution assay in irradiated mice, flow cytometry for CD25/CD4/CD8, genetic epistasis with cytokine neutralization\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo reconstitution assay with defined cellular phenotype, single lab\",\n      \"pmids\": [\"7541554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NIK (NF-κB-inducing kinase) was identified as a MAP3K-related kinase that participates in NF-κB induction by IL-1. Expression of kinase-deficient NIK mutants blocked NF-κB induction by IL-1 (as well as by TNF and CD95 signaling), establishing NIK as part of a common NF-κB-inducing signaling cascade downstream of the IL-1 type-I receptor.\",\n      \"method\": \"Yeast two-hybrid (Traf2 binding), expression of dominant-negative kinase mutants in cells, NF-κB reporter assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — dominant-negative mutagenesis of kinase combined with reporter assays, multiple receptor systems tested, widely replicated concept\",\n      \"pmids\": [\"9020361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"IL-1α and IL-1β are produced by resident macrophages within human islets of Langerhans in response to TNF + LPS + IFN-γ stimulation. Endogenously released IL-1 drives iNOS expression and nitric oxide production in beta cells, resulting in inhibition of glucose-stimulated insulin secretion. The IL-1 receptor antagonist protein (IRAP) blocked these effects, demonstrating a paracrine IL-1 → iNOS → NO → insulin secretion inhibition axis.\",\n      \"method\": \"RT-PCR for IL-1α/β mRNA, immunohistochemical colocalization with CD69 macrophage marker, IL-1Ra blockade, aminoguanidine (iNOS inhibitor), nitrite assay, insulin secretion assay\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (molecular, pharmacological, cellular), mechanistic pathway established with specific inhibitors\",\n      \"pmids\": [\"9691088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The cytoplasmic domain of IL-1R type I (IL-1Rcd) directly associates with RhoA and Rac-1 (but not p21Ras). IL-1 stimulation rapidly activates nucleotide exchange on RhoA and induces actin stress fiber formation in a Rho-dependent manner. RhoA association with IL-1Rcd is required for IL-1-directed NF-κB/IL-6 transcriptional activation and for IL-1R-associated MBP kinase activity.\",\n      \"method\": \"GST pulldown of RhoA/Rac-1 from cell extracts, coimmunoprecipitation with anti-IL-1R antibody, C3 transferase ADP-ribosylation assay, dominant-inhibitory RhoA transfection, reporter gene (IL-6 promoter), gel kinase assay\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical interaction (GST pulldown + Co-IP) combined with functional mutagenesis and kinase assays in a single study\",\n      \"pmids\": [\"10359565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IRAK (IL-1 receptor-associated kinase) is activated by LPS in macrophages through a TLR4-dependent mechanism. IRAK-deficient macrophages are resistant to LPS-induced signaling and show impaired TNF-α production. IRAK-deficient mice withstand lethal LPS challenge, establishing IRAK as a critical signaling mediator shared between the IL-1/IL-18 receptor and TLR pathways.\",\n      \"method\": \"IRAK knockout macrophages, LPS stimulation, signaling cascade analysis, TNF-α production assay, in vivo LPS lethality model\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple cellular and in vivo phenotypic readouts, functionally establishes pathway position\",\n      \"pmids\": [\"10754329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Leishmania major activates IL-1α promoter activity and mRNA expression in macrophages through a MyD88-dependent pathway. Dominant-negative MyD88 transfection and peritoneal macrophages from MyD88−/− mice both showed inhibited IL-1α promoter/mRNA responses to L. major. Despite mRNA induction, no IL-1α protein was detectable in cell lysates or supernatants, indicating additional anti-inflammatory pathways suppress IL-1α translation.\",\n      \"method\": \"Cytokine promoter-luciferase reporter transfection, dominant-negative MyD88 expression, MyD88−/− knockout macrophages, RT-PCR, ELISA\",\n      \"journal\": \"Microbes and Infection\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout and dominant-negative plus reporter assays, single lab, establishes MyD88 as upstream regulator of IL-1α transcription\",\n      \"pmids\": [\"12270723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TNF induces stromal cell expression of IL-1 and IL-1 receptor type I (IL-1RI). IL-1 (both α and β forms) then mediates TNF-induced RANKL expression by bone marrow stromal cells and directly stimulates osteoclast precursor differentiation via p38 MAPK, accounting for ~50% of TNF-induced osteoclastogenesis. IL-1Ra or IL-1RI deficiency abolished this TNF→IL-1→RANKL pathway.\",\n      \"method\": \"IL-1Ra treatment, IL-1RI-knockout stromal cells, co-culture osteoclastogenesis assay, in vivo TNF administration to IL-1RI-KO mice, p38 MAPK inhibition\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout combined with pharmacological blockade and in vivo validation, mechanistic pathway established with multiple orthogonal approaches\",\n      \"pmids\": [\"15668736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Central IL-1 receptor signaling via hypothalamic IL-1RI normally restrains bone resorption; IL-1RI-deficient mice and mice with CNS-targeted IL-1Ra overexpression (under GFAP promoter) both exhibited low bone mass and impaired bone growth characterized by doubled osteoclast number. This phenotype occurred without changes in testosterone or corticosterone, suggesting a neural pathway distinct from the HPA and gonadal axes.\",\n      \"method\": \"IL-1RI knockout mice, CNS-targeted IL-1Ra transgenic mice (GFAP promoter), bone histomorphometry, serum hormone measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent genetic mouse models with convergent bone phenotype, establishing central IL-1R signaling role in bone homeostasis\",\n      \"pmids\": [\"16126903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Intratesticular administration of IL-1α in adult rats disrupted blood-testis barrier (BTB) integrity and caused Sertoli-germ cell adhesion loss without altering steady-state levels of BTB proteins (OCLN, CLDN1, F11R, TJP1, CDH2). Instead, IL-1α altered the subcellular localizations of OCLN, F11R, and TJP1 away from cell-cell contact sites and disrupted the orderly arrangement of filamentous actin at the BTB and apical ectoplasmic specialization.\",\n      \"method\": \"Intratesticular IL-1α injection, inulin-FITC BTB integrity assay, Western blotting, immunofluorescence localization, phalloidin staining for F-actin\",\n      \"journal\": \"Biology of Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo functional experiment with multiple molecular readouts establishing actin cytoskeleton as IL-1α's primary cellular target in BTB regulation, single lab\",\n      \"pmids\": [\"18057314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The SNP at position +4845 of IL1A (G/T, encoding Ala or Ser at amino acid 114 of precursor IL-1α) affects enzymatic efficiency of calpain in cleaving precursor IL-1α. A 100-fold higher calpain concentration was required to process pre-IL-1α containing Ala (GG genotype, enriched in SSc patients) compared to Ser (TT genotype). The -889 C/T promoter SNP did not significantly affect transcriptional activity in fibroblasts.\",\n      \"method\": \"Luciferase reporter assay for promoter SNP, Western blotting after calpain titration of cell lysates from fibroblasts with defined +4845 genotypes\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic processing assay with defined genetic variants, single lab, mechanistically links SNP to calpain cleavage efficiency\",\n      \"pmids\": [\"17440718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Listeria-infected epithelial cells release IL-1α, which signals neighboring keratinocytes in a paracrine manner through the IL-1 receptor to upregulate S100A8/A9 expression and confer resistance to bacterial invasion. shRNA knockdown of S100A8/A9 reversed IL-1α-mediated resistance, establishing the IL-1α → IL-1R → S100A8/A9 axis as the mechanism of keratinocyte antibacterial defense.\",\n      \"method\": \"L. monocytogenes infection assay, conditioned media transfer, IL-1R antagonist blockade, shRNA knockdown of S100A8/A9, intracellular bacterial quantification\",\n      \"journal\": \"Mucosal Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal interventions (receptor antagonist + shRNA knockdown) with functional bacterial invasion readout, mechanistic pathway established\",\n      \"pmids\": [\"22031183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Crystal structure of the IL-1β–IL-1RI–IL-1RAcP signaling complex was determined, revealing that IL-1-type cytokines initiate signaling by binding a primary receptor that recruits an accessory protein to form a signaling-competent heterotrimeric complex, and establishing an evolutionary relationship between IL-1R and fibroblast growth factor receptor family.\",\n      \"method\": \"X-ray crystallography of the ternary IL-1β/IL-1RI/IL-1RAcP complex\",\n      \"journal\": \"Nature Structural & Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure of the complete signaling complex, definitive structural mechanism\",\n      \"pmids\": [\"22426547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"mTOR/TORC1 selectively promotes translation of membrane-bound IL-1α in senescent cells. Rapamycin suppressed IL-1α translation (but not mRNA levels), thereby reducing NF-κB transcriptional activity and downstream SASP cytokine secretion (IL-6 and others). Exogenous IL-1α restored IL-6 secretion in rapamycin-treated senescent cells, establishing IL-1α as a key upstream regulator of the SASP through NF-κB.\",\n      \"method\": \"Rapamycin treatment, IL-1α protein/mRNA quantification, cytokine ELISA, NF-κB reporter assay, exogenous IL-1α rescue experiment, in vivo tumor growth assay with senescent fibroblasts\",\n      \"journal\": \"Nature Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological and rescue experiments with multiple orthogonal readouts establishing mTOR→IL-1α translation→NF-κB→SASP pathway\",\n      \"pmids\": [\"26147250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Aging bone marrow myeloid cells produce increasing amounts of IL-1α and IL-1β in steady state; exposure to microbial products (TLR4/TLR8 ligands from gut microbiota) drives this IL-1 production. Signaling through IL-1R1 on hematopoietic stem cells drives myeloid-biased aging phenotype. IL-1R1 knockout mice, germ-free mice, antibiotic treatment, or pharmacologic IL-1 blockade all reversed myeloid-biased HSC output, establishing the microbiome/IL-1/IL-1R1 axis as a driver of HSC inflammaging.\",\n      \"method\": \"IL-1R1 knockout mice, germ-free mice, antibiotic treatment, in vitro cytokine stimulation, bone marrow transplantation, transcriptomic analysis of HSCs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple independent genetic and pharmacological interventions with convergent functional readout in vivo, mechanistic pathway from microbiome to IL-1 to HSC aging established\",\n      \"pmids\": [\"34525198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-1α (and IL-1β) signaling through IL-1R1 drives clonal expansion of Tet2+/− hematopoietic stem and progenitor cells (HSPCs) during aging. IL-1α treatment increased Tet2+/− HSPC cell cycle progression, multilineage differentiation, and repopulation capacity relative to wild-type HPSCs. Genetic deletion of IL-1R1 in Tet2+/− HSPCs or pharmacologic IL-1 inhibition impaired Tet2+/− clonal expansion, establishing the IL-1/IL-1R1 axis as a therapeutically targetable driver of TET2-mutant clonal hematopoiesis.\",\n      \"method\": \"Bone marrow transplantation, genetic mosaicism mouse model (HSC-SCL-Cre-ERT; Tet2+/flox), IL-1α administration, IL-1R1 conditional knockout, pharmacologic IL-1 inhibition, cell cycle analysis, transcriptomic analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacologic interventions with in vivo functional readouts, replicated across approaches\",\n      \"pmids\": [\"36379023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A de novo gain-of-function missense variant in IL-1R1 (p.Lys131Glu) disrupts binding of the antagonist IL-1Ra but not IL-1α or IL-1β, resulting in unopposed IL-1 signaling and autoinflammation (CRMO). Mice with the homologous mutation showed hyperinflammation and pathological osteoclastogenesis. This structural insight was used to design an IL-1 therapeutic that traps IL-1α and IL-1β but spares IL-1Ra.\",\n      \"method\": \"Patient PBMC transcriptomics, mutant mouse model, binding assays for IL-1Ra/IL-1α/IL-1β to mutant receptor, collagen antibody-induced arthritis model, structure-guided drug design\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — combined patient genetics, functional receptor binding assays, in vivo mouse model, and structure-guided therapeutic design\",\n      \"pmids\": [\"37315560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Age-associated decline of DNA methyltransferase 3A (DNMT3A) in hematopoietic myeloid progenitor-like cells enhances IL-1α production. These cells accumulate in lung tumors with aging and drive emergency myelopoiesis via IL-1α. Disrupting IL-1R1 signaling early in tumor development normalized myelopoiesis and slowed lung, colonic, and pancreatic tumor growth.\",\n      \"method\": \"Hematopoietic aging chimera experiments, DNMT3A loss-of-function, IL-1α quantification, IL-1R1 genetic disruption, tumor growth assays in multiple cancer models, human tumor single-cell analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic interventions, multiple tumor models, mechanistic link from DNMT3A → IL-1α → myelopoiesis → tumor progression established\",\n      \"pmids\": [\"39236155\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-1α is a dual-compartment cytokine: the membrane-associated/nuclear precursor form is constitutively expressed in epithelial and myeloid cells and acts as a damage-associated alarmin (DAMP) that is released upon necrosis, while its mTOR-regulated translation drives NF-κB-dependent SASP in senescent cells; upon binding IL-1R1 (a three-immunoglobulin-domain receptor that recruits IL-1RAcP to form a signaling-competent heterotrimer), IL-1α activates downstream signaling via IRAK and NIK kinases leading to NF-κB and MAPK pathway activation, with RhoA physically associating with the IL-1R cytoplasmic domain to amplify cytoskeletal and transcriptional responses; IL-1α also regulates tissue-specific processes including blood-testis barrier restructuring via actin cytoskeletal reorganization, keratinocyte antibacterial defense through paracrine S100A8/A9 induction, thymocyte CD25 induction and T cell lineage commitment, bone resorption restraint via central hypothalamic IL-1R1 signaling, and hematopoietic stem cell aging and clonal hematopoiesis expansion through IL-1R1 on HSPCs.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IL-1α is a pleiotropic pro-inflammatory cytokine whose precursor is constitutively expressed in epithelial and myeloid cells and which signals through the type I IL-1 receptor (IL-1R1) to drive NF-κB- and MAPK-dependent inflammatory programs [#1, #16]. The receptor, a three-immunoglobulin-domain protein that binds IL-1α and IL-1β indistinguishably, initiates signaling by recruiting the accessory protein IL-1RAcP to assemble a signaling-competent heterotrimeric complex [#0, #17]. Downstream, the IL-1R1 cytoplasmic domain engages the kinases IRAK and NIK to activate NF-κB, while directly associating with RhoA and Rac-1 to couple receptor engagement to actin stress fiber formation and amplified NF-κB/IL-6 transcription [#7, #9, #10]. IL-1α expression and processing are controlled at multiple levels: keratinocyte transcription is constitutive and modulated by LPS, UV, and differentiation state [#1]; calpain cleaves the precursor with efficiency that depends on a coding polymorphism [#15]; and mTOR/TORC1 selectively promotes IL-1α translation in senescent cells to drive NF-κB-dependent SASP cytokine secretion [#18]. Through IL-1R1, IL-1α governs diverse tissue processes including paracrine S100A8/A9-mediated keratinocyte antibacterial defense [#16], blood-testis barrier restructuring via actin reorganization [#14], thymocyte CD25 induction and T cell lineage commitment [#6], central hypothalamic restraint of bone resorption [#13], and TNF-induced RANKL-dependent osteoclastogenesis [#12]. In aging, myeloid-derived IL-1α driven by microbial signals and DNMT3A decline acts on IL-1R1 on hematopoietic stem/progenitor cells to promote myeloid-biased aging, clonal expansion of TET2-mutant clones, emergency myelopoiesis, and tumor progression [#19, #20, #22]. A gain-of-function IL-1R1 variant that abolishes IL-1Ra binding causes the autoinflammatory disease CRMO, underscoring the pathological consequence of unopposed IL-1 signaling [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing the molecular identity of the IL-1 receptor defined how IL-1α and IL-1β share a single signaling entry point.\",\n      \"evidence\": \"cDNA expression cloning from mouse T cells with receptor-binding validation\",\n      \"pmids\": [\"2969618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how the receptor distinguishes agonist from antagonist\", \"Cytoplasmic signaling machinery not yet defined\", \"No accessory subunit identified\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Demonstrating constitutive, condition-responsive IL-1α expression in keratinocytes established epithelial cells as a source of IL-1α independent of IL-1β.\",\n      \"evidence\": \"Northern blotting and IL-1 bioassay in keratinocyte culture under defined Ca²⁺ and LPS/UV conditions\",\n      \"pmids\": [\"3258334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking differentiation state to expression unresolved\", \"Did not define release or signaling consequences\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Chronic in vivo IL-1α exposure was shown to drive selective skeletal muscle protein catabolism, defining a systemic catabolic action.\",\n      \"evidence\": \"Chronic cytokine administration in rats with protein fractionation and muscle mRNA Northern blotting\",\n      \"pmids\": [\"2784290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/signaling pathway mediating muscle wasting not identified\", \"Tissue selectivity mechanism unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Internalization of the IL-1α–receptor complex into nuclei and the regulation of IL-1β bioactivity by α2-macroglobulin sequestration revealed post-binding control of IL-1 action.\",\n      \"evidence\": \"125I-IL-1 internalization with EM autoradiography and nuclear fractionation; native PAGE binding/release assays with thioredoxin and bioassays\",\n      \"pmids\": [\"2137488\", \"1700994\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of nuclear receptor translocation not established\", \"Physiological relevance of α2M sequestration in vivo unresolved\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Chromosomal mapping placed IL1A, IL1B, and IL1R1 in proximity on human 2q, framing the genomic organization of the IL-1 system.\",\n      \"evidence\": \"Hybrid cell segregation, in situ hybridization, and RFLP analysis in human and mouse\",\n      \"pmids\": [\"1672292\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional consequence of genomic clustering established\", \"Regulatory linkage not addressed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying IL-1α as necessary for thymocyte CD25 induction and CD4/CD8 differentiation extended IL-1α function to T cell development.\",\n      \"evidence\": \"Thymus reconstitution in irradiated mice with flow cytometry and cytokine neutralization epistasis\",\n      \"pmids\": [\"7541554\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not separate IL-1α from TNF-α requirement molecularly\", \"Receptor-level signaling in thymocytes not dissected\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Placing NIK in the IL-1-to-NF-κB cascade identified a shared kinase node converging IL-1, TNF, and CD95 signaling onto NF-κB.\",\n      \"evidence\": \"Yeast two-hybrid and dominant-negative kinase expression with NF-κB reporter assays\",\n      \"pmids\": [\"9020361\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise position relative to IRAK not resolved here\", \"Endogenous requirement not tested genetically in this study\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating a paracrine IL-1 → iNOS → NO axis in pancreatic islets established IL-1α as a driver of beta-cell dysfunction.\",\n      \"evidence\": \"RT-PCR, macrophage colocalization, IL-1Ra blockade, iNOS inhibition, and insulin secretion assays in human islets\",\n      \"pmids\": [\"9691088\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of IL-1α vs IL-1β not separated\", \"Long-term beta-cell fate not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that the IL-1R cytoplasmic domain directly binds RhoA/Rac-1 connected receptor engagement to cytoskeletal remodeling and transcriptional output.\",\n      \"evidence\": \"GST pulldown, Co-IP, C3 transferase, dominant-inhibitory RhoA, IL-6 promoter reporter, and gel kinase assays\",\n      \"pmids\": [\"10359565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Adaptor bridging receptor to RhoA not defined\", \"Reciprocal in vivo validation absent\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Genetic ablation of IRAK established it as an essential signaling mediator shared between IL-1/IL-18 and TLR pathways.\",\n      \"evidence\": \"IRAK knockout macrophages and in vivo LPS lethality model with TNF-α production readouts\",\n      \"pmids\": [\"10754329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"IL-1α-specific (vs IL-1β/TLR) requirement not isolated\", \"Downstream substrate connections not mapped here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linking IL-1α transcription to MyD88 revealed pathogen-driven upstream regulation while uncoupling mRNA induction from protein output.\",\n      \"evidence\": \"Promoter-luciferase reporter, dominant-negative MyD88, MyD88−/− macrophages, RT-PCR and ELISA after L. major infection\",\n      \"pmids\": [\"12270723\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Translational/processing block preventing protein accumulation not identified\", \"Single pathogen context\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Two studies defined IL-1's role in bone homeostasis: peripherally driving TNF-induced RANKL/osteoclastogenesis and centrally restraining bone resorption via hypothalamic IL-1R1.\",\n      \"evidence\": \"IL-1RI-knockout stromal cells, co-culture osteoclastogenesis, p38 inhibition, and CNS-targeted IL-1Ra transgenic mice with bone histomorphometry\",\n      \"pmids\": [\"15668736\", \"16126903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"IL-1α vs IL-1β contribution to each arm not separated\", \"Neural circuitry of central restraint undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Two studies established IL-1α's regulation of the blood-testis barrier via actin reorganization and a coding SNP controlling calpain processing efficiency.\",\n      \"evidence\": \"Intratesticular IL-1α injection with BTB integrity, immunolocalization, and phalloidin staining; calpain titration of fibroblast lysates with defined +4845 genotypes\",\n      \"pmids\": [\"18057314\", \"17440718\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway from IL-1R1 to actin in Sertoli cells not mapped\", \"Clinical impact of processing-efficiency SNP not functionally proven in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defining the IL-1α → IL-1R → S100A8/A9 paracrine axis established a mechanism for epithelial antibacterial defense.\",\n      \"evidence\": \"L. monocytogenes infection, conditioned media transfer, IL-1R antagonist, and S100A8/A9 shRNA knockdown with bacterial quantification\",\n      \"pmids\": [\"22031183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mode of IL-1α release from infected cells not defined\", \"Generalizability beyond Listeria untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The crystal structure of the IL-1β/IL-1RI/IL-1RAcP complex defined the heterotrimeric receptor assembly that initiates IL-1-type signaling.\",\n      \"evidence\": \"X-ray crystallography of the ternary signaling complex\",\n      \"pmids\": [\"22426547\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure solved with IL-1β rather than IL-1α\", \"Cytoplasmic assembly of adaptors not captured\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying mTOR-dependent translational control of membrane IL-1α positioned IL-1α as the upstream NF-κB driver of the senescence-associated secretory phenotype.\",\n      \"evidence\": \"Rapamycin treatment with IL-1α protein/mRNA quantification, NF-κB reporter, cytokine ELISA, and exogenous IL-1α rescue in senescent fibroblasts\",\n      \"pmids\": [\"26147250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of selective IL-1α mRNA translation not resolved\", \"In vivo SASP relevance only partially addressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining the microbiome/IL-1/IL-1R1 axis established myeloid-derived IL-1α as a driver of hematopoietic stem cell inflammaging.\",\n      \"evidence\": \"IL-1R1 knockout, germ-free and antibiotic-treated mice, bone marrow transplantation, and HSC transcriptomics\",\n      \"pmids\": [\"34525198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"IL-1α vs IL-1β specific contribution not fully separated\", \"Molecular events downstream of IL-1R1 in HSCs not detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Two studies established the IL-1/IL-1R1 axis as a driver of TET2-mutant clonal hematopoiesis and identified a CRMO-causing gain-of-function IL-1R1 variant that abolishes antagonist binding.\",\n      \"evidence\": \"Tet2+/− mosaic mouse models with IL-1α administration and IL-1R1 conditional knockout; patient genetics, mutant receptor binding assays, mouse arthritis model, and structure-guided drug design\",\n      \"pmids\": [\"36379023\", \"37315560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-1α or IL-1β dominates clonal expansion not resolved\", \"Human therapeutic efficacy of antagonist-sparing trap not yet clinically validated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linking age-associated DNMT3A decline to IL-1α-driven emergency myelopoiesis connected hematopoietic aging to tumor progression across cancer types.\",\n      \"evidence\": \"Hematopoietic aging chimeras, DNMT3A loss-of-function, IL-1R1 genetic disruption, multiple tumor models, and human tumor single-cell analysis\",\n      \"pmids\": [\"39236155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which DNMT3A loss enhances IL-1α specifically not detailed\", \"Translation to human therapy not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the distinct activities of IL-1α — nuclear/precursor alarmin functions, calpain-dependent processing, and receptor-mediated signaling — are integrated and differentiated from IL-1β at the cellular level remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Most in vivo studies do not separate IL-1α from IL-1β contributions\", \"Functional role of nuclear IL-1α localization uncharacterized\", \"Direct structure of the IL-1α (vs IL-1β) ternary receptor complex not in corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 16, 17]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [16, 19, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 9, 10]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"complexes\": [\n      \"IL-1α/IL-1R1/IL-1RAcP signaling complex\"\n    ],\n    \"partners\": [\n      \"IL1R1\",\n      \"IL1RAP\",\n      \"RHOA\",\n      \"RAC1\",\n      \"IRAK1\",\n      \"MAP3K14\",\n      \"A2M\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":{"gene":"IL1A","tier":"IDENTITY","verdict":"Identity concern","subtype":"corpus_ungrounded","uniprot_band":"rich","rules_fired":"R1","issue":"R1: gene named in 12/100 (12%) of its own corpus abstracts (< 25%) — corpus likely a paralog/alias collision"},"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}